1. Home
  2. ECO vs ANNX Comparison

ECO vs ANNX Comparison

Compare ECO & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Okeanis Eco Tankers Corp.

ECO

Okeanis Eco Tankers Corp.

N/A

Current Price

$45.48

Market Cap

1.1B

Sector

N/A

ML Signal

N/A

Logo Annexon Inc.

ANNX

Annexon Inc.

N/A

Current Price

$5.50

Market Cap

730.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ECO
ANNX
Founded
2018
2011
Country
Greece
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
730.4M
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
ECO
ANNX
Price
$45.48
$5.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$42.00
$16.50
AVG Volume (30 Days)
529.9K
2.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.00%
N/A
EPS Growth
N/A
42.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.07
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$18.60
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.91
$1.29
52 Week High
$57.29
$7.18

Technical Indicators

Market Signals
Indicator
ECO
ANNX
Relative Strength Index (RSI) 45.39 49.19
Support Level $36.82 $4.69
Resistance Level $57.29 $5.61
Average True Range (ATR) 1.94 0.34
MACD -0.95 0.07
Stochastic Oscillator 0.00 40.70

Price Performance

Historical Comparison
ECO
ANNX

About ECO Okeanis Eco Tankers Corp.

Okeanis Eco Tankers Corp owns and operates tanker vessels in Greece. The business of the company is to own, charter out, and operate tanker vessels. The company owns, through its vessel-owning subsidiaries, a fleet of around seven tanker vessels and has around eight tanker vessels on order. The sailing fleet consists of around six modern Suezmax tankers and eight VLCC tankers.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: